Prostatype Genomics Navigation
  • THE PROSTATYPE® TEST SYSTEM
    • Prostate cancer and the prognostic challenge
    • Prostatype – The solution
    • Why Prostatype?
    • Resources
      • Publications and Posters
      • White Paper
      • Technical Documents
    • Legal
    • Visit Prostatype® web site
  • ABOUT US
    • Company in brief
    • Mission and Vision
    • History
    • Board of directors
    • Senior management
    • Corporate group structure
    • Advisory Board
    • Careers
  • PRESS & NEWS
  • INVESTOR RELATIONS
    • Reports and presentations
    • Analyst coverage
    • Financial calendar
    • Share and shareholder information
    • Corporate governance
    • IPO
    • IR contact
    • Certified Adviser
  • Contact
  • THE PROSTATYPE® TEST SYSTEM
    • Prostate cancer and the prognostic challenge
    • Prostatype – The solution
    • Why Prostatype?
    • Resources
      • Publications and Posters
      • White Paper
      • Technical Documents
    • Legal
    • Visit Prostatype® web site
  • ABOUT US
    • Company in brief
    • Mission and Vision
    • History
    • Board of directors
    • Senior management
    • Corporate group structure
    • Advisory Board
    • Careers
  • PRESS & NEWS
  • INVESTOR RELATIONS
    • Reports and presentations
    • Analyst coverage
    • Financial calendar
    • Share and shareholder information
    • Corporate governance
    • IPO
    • IR contact
    • Certified Adviser
  • Contact


Contact

Gustaf III:s Boulevard 34
169 73 Solna
+46 (0)8-20 87 00‬‬
info@prostatypegenomics.com

Prostatype.se

Menu

THE PROSTATYPE® TEST SYSTEM
ABOUT US
PRESS & NEWS
INVESTOR RELATIONS
CONTACT

EIT Health

Subscribe

    Hemsida skapad av Webb & SEO Byrå Hjalmar&Company

    SITEMAP I Privacy Policy

    A Message from Prostatype Genomics AB Regarding COVID-19. In response to the COVID-19 outbreak the World Health Organization (WHO) declared a pandemic on Wednesday 11th March 2020.

    Read more!
    X